China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 14, 2019 and accepted by EDGAR at Aug 14, 2019, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $2.6m | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $5.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $2.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $4.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $163.5k | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $820.1k | us-gaap:GrossProfit |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $66.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $135.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$753.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $97.3k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $184.0k | us-gaap:InterestExpense |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$838.1k | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $931.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $73.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $7.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $43.0m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $9.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $14.1m | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | $6.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-06-30 | $29.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-19-015792. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.